DOCSLIB.ORG

Propanenitrile Derivatives As Orally Active AMPA Receptor Antagonists

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Propanenitrile Derivatives As Orally Active AMPA Receptor Antagonists Vol. 67, No. 7 Chem. Pharm. Bull. 67, 699–706 (2019) 699 Regular Article Synthesis and Pharmacological Evaluation of 3-[(4-Oxo-4H-pyrido[3,2- e][1,3]thiazin-2-yl)(phenyl)amino]propanenitrile Derivatives as Orally Active AMPA Receptor Antagonists Hiroshi Inami,* Jun-ichi Shishikura, Tomoyuki Yasunaga, Masaaki Hirano, Takenori Kimura, Hiroshi Yamashita, Kazushige Ohno, and Shuichi Sakamoto† Drug Discovery Research, Astellas Pharma Inc.; 21 Miyukigaoka, Tsukuba, Ibaraki 305–8585, Japan. Received December 11, 2018; accepted April 24, 2019 In our search for novel orally active α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, we found that conversion of an allyl group in the lead compound 2-[allyl(4-methyl- phenyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one (4) to a 2-cyanoethyl group significantly increased in- hibitory activity against AMPA receptor-mediated kainate-induced toxicity in rat hippocampal cultures. Here, we synthesized 10 analogs bearing a 2-cyanoethyl group and administered them to mice to evaluate their anticonvulsant activity in maximal electroshock (MES)- and pentylenetetrazol (PTZ)-induced seizure tests, and their effects on motor coordination in a rotarod test. 3-{(4-Oxo-4H-pyrido[3,2-e][1,3]thiazin- 2-yl)[4-(trifluoromethoxy)phenyl]amino}propanenitrile (25) and 3-[(2,2-difluoro-2H-1,3-benzodioxol-5-yl)- (4-oxo-4H-pyrido[3,2-e][1,3]thiazin-2-yl)amino]propanenitrile (27) exhibited potent anticonvulsant activity in both seizure tests and induced minor motor disturbances as indicated in the rotarod test. The protective index values of 25 and 27 for MES-induced seizures (10.7 and 12.0, respectively) and PTZ-induced seizures (6.0 and 5.6, respectively) were considerably higher compared with those of YM928 (5) and talampanel (1). Key words kainate-induced neurotoxicity; anticonvulsant activity; protective index; α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid receptor antagonist Introduction have been well investigated.9) In studies employing a rat kin- Epilepsy, one of the most common neurological disorders, dling model of complex partial seizures, selective NMDA re- affects approximately 65 million people worldwide and is ceptor antagonists exert only weak anticonvulsant effects with characterized by recurrent unprovoked seizures caused by an marked behavioral side effects such as hyperactivity and ste- imbalance between excitatory and inhibitory neurotransmis- reotypies.10) Consistent with these results, the selective NMDA 1) sion. Although more than 40 antiepileptic drugs (AEDs) receptor antagonist D-CPP-ene failed to suppress intractable are currently on the market, they are ineffective for control- complex partial seizures in a clinical trial.11) In contrast, se- ling symptoms in approximately one-third of patients, and lective AMPA receptor antagonists have broad-spectrum an- third-generation AEDs, first marketed in the 1980 s, have not ticonvulsant activity in seizure animal models, including the decreased the proportion of intractable patients.2) Moreover, rat kindling model, and do not cause cognitive dysfunction or AED therapies are frequently associated with adverse effects psychiatric effects associated with NMDA receptor antago- on the central nervous system (CNS) such as sedation, motor nists.9,12–14) Compounds such as the noncompetitive antagonists disturbances, cognitive dysfunction, and psychiatric effects, talampanel (1)15,16) and perampanel (2),17,18) as well as the com- as well as idiosyncratic and other adverse effects, which seri- petitive antagonist selurampanel (3)19,20) (Fig. 1) were developed ously impair quality of life.3) Therefore, more effective and to treat epilepsy, with perampanel (2) being the first AMPA safer AEDs must be developed.4) receptor antagonist introduced to the market in 2012. However, Most available AEDs have multiple and complementary despite intense efforts to develop AMPA receptor antagonists, mechanisms of action, which can be categorized as blockade few such drug candidates are currently in clinical development. of voltage-dependent Na+ and/or Ca2+ channels, potentiation of In our search for a novel class of orally active AMPA γ-aminobutyric acid (GABA)-mediated inhibitory neurotrans- receptor antagonists, we identified 2-[allyl(4-methylphenyl)- mission, and reduction of glutamate-mediated excitatory neu- amino]-4H-pyrido[3,2-e][1,3] thiazin-4-one (4) (Fig. 2) as a rotransmission.5) Glutamate is a major neurotransmitter in the lead compound that inhibits AMPA receptor-mediated kain- vertebrate CNS and plays an essential role in fast excitatory ate-induced toxicity in rat hippocampal cultures.21,22) A subse- neurotransmission via the activation of ionotropic glutamate quent structure–activity relationship (SAR) study of the sub- receptors including N-methyl-D-aspartate (NMDA), α-amino-3- stituted phenyl ring attached to the 2-amino group led to the hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kai- discovery of the selective and noncompetitive AMPA receptor nate receptors.6–8) The former two subtypes are most abundant, antagonist 2-[(4-chlorophenyl)(methyl) amino]-4H-pyrido[3,2- and the effects of their antagonists in seizure animal models e] [ 1 , 3 ] t h i a z i n - 4 - o n e ( 5) (YM928) (Fig. 2) and its analogs.22,23) Oral administration of 5 resulted in a broad spectrum of anti- 24–26) † Present address: Solasia Pharma K.K.; 4F Sumitomo Fudosan Shiba-koen convulsant activity in various seizure animal models. Tower, 2–11–1 Shiba-koen, Minato-ku, Tokyo 105–0011, Japan. Our alternative approach to enhance inhibitory activity * To whom correspondence should be addressed. e-mail: [email protected] © 2019 The Pharmaceutical Society of Japan 700 Chem. Pharm. Bull. Vol. 67, No. 7 (2019) Fig. 1. Structures of AMPA Receptor Antagonists Fig. 3. Structure of 1-Phenyl-1,2,3,4-tetrahydroisoquinoline AMPA Receptor Antagonist 6 Fig. 2. Structures of Lead Compound 4 and YM928 (5) against kainate-induced neurotoxicity focused on the structur- al modification of the allyl group in 4. In previous SAR stud- ies of 1-phenyl-1,2,3,4-tetrahydroisoquinoline derivatives such as 6 (Fig. 3), a noncompetitive AMPA receptor antagonist, Gitto et al. suggested that the acetyl group at the 2-position, which may function as a hydrogen bond acceptor, positively influences AMPA receptor recognition and enhances anti- convulsant activity in some cases.27,28) Based on this finding and the structural similarities between 4 and 6, we designed novel 4H-pyrido[3,2-e][1,3] thiazin-4-one derivatives bearing a cyano group, which possesses hydrogen bond acceptor abil- ity, on an alkyl substituent attached to the 2-amino group. Here, we describe the synthesis and pharmacological evalua- tion of 10 3-[(4-oxo-4H-pyrido[3,2-e][1,3] thiazin-2-yl)(phenyl)- Reagents and conditions: (a) NH4SCN, acetone, then 3-anilinopropanenitrile. amino] propanenitrile derivatives as novel AMPA receptor Chart 1 antagonists. Four of these compounds demonstrated marked anticonvulsant activity in maximal electroshock (MES)- and without the need for further optimization of the reaction con- pentylenetetrazol (PTZ)-induced seizure tests (MES and PTZ ditions.30) tests). Moreover, two of these compounds induced consider- ably less motor disturbances as demonstrated in a rotarod test Results and Discussion compared with YM928 (5) and talampanel (1). We first examined the effect of a 2-cyanoethyl group at- tached to the 2-amino group of the 4H-pyrido[3,2-e] [1,3]- Chemistry thiazin-4-one ring on inhibitory activity against kainate-in- 3-[(4-Oxo-4H-pyrido[3,2-e][1,3] thiazin-2-yl)(phenyl) amino]- duced neurotoxicity. As shown in Table 1, introduction of the propanenitrile derivatives 18–27 were synthesized by adding 2-cyanoethyl group (20) led to a 5-fold increase in inhibitory the appropriate 3-anilinopropanenitriles to 2-chloronicotinoyl activity compared with allyl (4) or methyl (7) groups. isothiocyanate, which was prepared from 2-chloronicotinoyl Encouraged by these results, we next evaluated the chloride (17) (48–87% yields)22,29) (Chart 1). The 3-anilinopro- pharmacological activity of 3-[(4-oxo-4H-pyrido[3,2-e] [1,3]- panenitriles used here were synthesized by aza-Michael addi- thiazin-2-yl)(phenyl) amino] propanenitrile derivatives 18–27 tion of anilines to acrylonitrile. In this reaction, we examined containing different substituents on the phenyl ring. The re- the effects of catalysts such as Dowex® 50WX4; montmoril- sults of a SAR study of corresponding N-methyl and N-ethyl lonite K10; molecular sieves 4A; Proton sponge; and acidic, analogs such as YM928 (5)22) suggested that compounds 18– neutral, and basic aluminas (data not shown). Among these, 27 should retain inhibitory activity with IC50 values less than acidic and neutral aluminas exhibited sufficient catalytic ac- 10 µM. Anticonvulsant activity was assessed in mice subjected tivity and afforded the desired product in acceptable yields to MES and PTZ tests, and the data are presented as the ED50. Vol. 67, No. 7 (2019) Chem. Pharm. Bull. 701 The effects of these compounds on motor coordination were tests. The results of these pharmacological evaluations for evaluated using the rotarod test, and the data are presented 18–27 and the N-methyl and N-ethyl analogs 5 and 8–16 are as the median toxic dose (TD50). These tests are widely used summarized in Table 2. in primary screens for novel AEDs.31,32) The protective index In the MES test of the N-methyl and N-ethyl analogs 5 and (PI), defined as TD50/ED50, was calculated for both seizure 8–16, the 4-chlorophenyl derivative YM928 (5) exhibited the highest anticonvulsant activity (ED50, 7.4 mg/kg) following oral administration.24) The anticonvulsant activity of the 4-fluoro- Table 1. Inhibitory Activity of 2-[(4-Methylphenyl)amino]-4H-pyrido[3,2- 22) e][1,3]thiazin-4-one Derivatives against Kainate-Induced Neurotoxicity phenyl (8), 4-bromophenyl (9), and 4-(trifluoromethyl) phenyl (10) derivatives were 2-, 3-, and >4-fold lower compared with that of 5, respectively.
Load more

Recommended publications
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.402,830 B2 Cialella Et Al
    USOO940283OB2 (12) United States Patent (10) Patent No.: US 9.402,830 B2 Cialella et al. (45) Date of Patent: * Aug. 2, 2016 (54) METHODS OF TREATING DYSKINESIA AND FOREIGN PATENT DOCUMENTS RELATED DSORDERS WO 93.18767 A1 9, 1993 (71) Applicant: Melior Discovery, Inc., Exton, PA (US) OTHER PUBLICATIONS (72) Inventors: John Ciallella, Exton, PA (US); John Afanasev et al., Effects of amphetamine and Sydnocarbon dopamine Gruner, Exton, PA (US); Andrew G. release and free radical generation in rat striatum, Pharmacol Reaume, Exton, PA (US); Michael S. Biochem Behav, 2001, 69(3-4):653-8. Saporito, Exton, PA (US) Anderzhanova et al., Effect of d-amphetamine and Sydnocarb on the extracellular level of dopamine, 3,4-dihydroxyphenylacetic acid, and (73) Assignee: Melior Discovery, Inc., Exton, PA (US) hydroxyl radicals generation in rat striatum, Ann NY AcadSci, 2000, 914:137-45. Anderzhanova et al., Effects of Sydnocarb and D-amphetamine on the (*) Notice: Subject to any disclaimer, the term of this extracellular levels of amino acids in the rat caudate-putamen, Eur J patent is extended or adjusted under 35 Pharmacol, 2001, 428(1):87-95. U.S.C. 154(b) by 0 days. Bashkatova et al., Neuroshemical changes and neurotoxic effects of This patent is Subject to a terminal dis an acute treatment with Sydnocarb, a novel psychostimulant: com claimer. parison with D-amphetamine, Ann NY AcadSci, 2002,965: 180-192. Cody, Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results, J Occup Environ Med, (21) Appl. No.: 14/702,242 2002, 44(5):435-50.
    [Show full text]
  • UNDERSTANDING PHARMACOLOGY of ANTIEPILEPTIC DRUGS: Content
    UNDERSTANDING PHARMACOLOGY OF ANTIEPILEPTIC DRUGS: PK/PD, SIDE EFFECTS, DRUG INTERACTION THANARAT SUANSANAE, BPharm, BCPP, BCGP Assistance Professor of Clinical Pharmacy Faculty of Pharmacy, Mahidol University Content Mechanism of action Pharmacokinetic Adverse effects Drug interaction 1 Epileptogenesis Neuronal Network Synaptic Transmission Stafstrom CE. Pediatr Rev 1998;19:342‐51. 2 Two opposing signaling pathways for modulating GABAA receptor positioning and thus the excitatory/inhibitory balance within the brain Bannai H, et al. Cell Rep 2015. doi: 10.1016/j.celrep.2015.12.002 Introduction of AEDs in the World (US FDA Registration) Mechanism of action Pharmacokinetic properties Adverse effects Potential to develop drug interaction Formulation and administration Rudzinski LA, et al. J Investig Med 2016;64:1087‐101. 3 Importance of PK/PD of AEDs in Clinical Practice Spectrum of actions Match with seizure type Combination regimen Dosage regimen Absorption Distribution Metabolism Elimination Drug interactions ADR (contraindications, cautions) Mechanisms of Neuronal Excitability Voltage sensitive Na+ channels Voltage sensitive Ca2+ channels Voltage sensitive K+ channel Receptor‐ion channel complex Excitatory amino acid receptor‐cation channel complexes • Glutamate • Aspartate GABA‐Cl‐ channel complex 4 Mechanism of action of clinically approved anti‐seizure drugs Loscher W, et al. CNS Drugs 2016;30:1055‐77. Summarize Mechanisms of Action of AEDs AED Inhibition of Increase in Affinity to Blockade of Blockade of Activation of Other glutamate GABA level GABAA sodium calcium potassium excitation receptor channels channels channels Benzodiazepines + Brivaracetam + + Carbamazepine + + (L) Eslicarbazepine + Ethosuximide + (T) Felbamate +(NMDA) + + + + (L) + Gabapentin + (N, P/Q) Ganaxolone + Lacosamide + Lamotrigine + + + + (N, P/Q, R, T) + inh. GSK3 Levetiracetam + + (N) SV2A, inh.
    [Show full text]
  • Whole Document
    Detailed Pharmacology Review of Neuroprotective agents for ALS TABLE OF CONTENTS Page 1. AEOL10150 ..2 2. Arimoclomol ..7 3. Ceftriaxone 10 4. Celastrol 14 5. CGP3446 18 6. Copaxone 21 7. Coenzyme Q10 25 8. Insulin Growth Factor-1 - AAV 31 9. Insulin Growth Factor-1 34 10. Memantine 38 11. Minocycline 41 12. NAALADase Inhibitors 47 13. NBQX 50 14. Nimesulide 53 15. Nimodipine 56 16. ONO2506 60 17. Sodium Phenylbutyrate 63 18. Riluzole 68 19. Scriptaid 73 20. Talampanel 76 21. Tamoxifen 79 22. Thalidomide 83 23. Trehalose 86 24. Vitamin E 89 Detailed pharmacology review of neuroprotective agents for ALS Traynor BJ et al. AEOL 10150 PARAMETER REVELANT INFORMATION IDENTITY AND GENERAL INFORMATION Drug Class Catalytic antioxidant Manufacturer Incara Pharmaceuticals, Inc. RTP, NC (Aeolus Pharmaceuticals) Regulatory Approval Status Investigational Mechanism of Antioxidant – downstream reduction in protein nitration and oxidation Action CASE FOR USE IN ALS Rationale Ongoing oxidative stress may be involved in the pathogenesis of ALS. Clinical Data None Animal Data Kiael M, 2004 (Abstract Only): AEOL 10150 (2.5 mg/kg/day, i.p.) was administered to G93A transgenic mice from the time of symptom onset, which was determined by a combination of tests (i.e., Rotarod performance at 15 rpm, appearance of tremor of the hind legs, and gait abnormalities). AEOL 10150 treatments attenuated weight loss, enhanced motor performance and increased the survival interval (time from symptom onset to death) by 38% in G93A mice. AEOL 10150 treatments also extended the survival in these mice by 14%. Crow JP, 2004 (presented at AAN): In four separate studies in two academic medical centers, 2 Prepared by Susan Fagan, Pharm D Version 17 th May 2005 Detailed pharmacology review of neuroprotective agents for ALS Traynor BJ et al.
    [Show full text]
  • Pdf4 Complex I and the Aryl Palladium Precursor II Underwent Sequential Single Electron Abstraction from Aryl Pd(II) Complex
    Design, synthesis, methodology development, and evaluation of PET imaging agents targeting cancer and CNS disorders By Gengyang Yuan B.S. in Chemical Engineering and Technology, Zhejiang University of Technology M.S. in Pharmaceutical Engineering, Zhejiang University A dissertation submitted to The Faculty of the College of Science of Northeastern University in partial fulfillment of the requirements for the degree of Doctor of Philosophy April 21, 2017 Dissertation directed by Michael P. Pollastri Associate Professor and Chair of Chemistry and Chemical Biology Co-directed by Neil Vasdev Adjunct Associate Professor of Chemsitry and Chemical Biology Associate Professor of Radiology, Massachusetts General Hospital and Harvard Medical School Dedication To my parents Zhijun and Yongmian and my wife Ran and daughter Isabella ii Acknowledgements This dissertation would not have been possible without the support, guidance and encouragement of numerous people who have helped me along the way. First and foremost, I would like to thank Northeastern University and the Department of Chemistry and Chemical Biology for supporting me to pursue my doctoral study. I would like to especially thank my current advisor Professor Michael Pollastri for helping me out when I needed it the most. I appreciate you for taking me into your group and giving me full support to finish my thesis projects. I also especially thank my co-advisor Professor Neil Vasdev for taking me into his group at Mass. General Hospital & Harvard Medical School and teaching me the PET radiochemistry and PET imaging. I could not image how I could accomplish this work without your help. I also got a lot of help from Dr.
    [Show full text]
  • Bumetanide Enhances Phenobarbital Efficacy in a Rat Model of Hypoxic Neonatal Seizures
    Bumetanide Enhances Phenobarbital Efficacy in a Rat Model of Hypoxic Neonatal Seizures The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Cleary, Ryan T., Hongyu Sun, Thanhthao Huynh, Simon M. Manning, Yijun Li, Alexander Rotenberg, Delia M. Talos, et al. 2013. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS ONE 8(3): e57148. Published Version doi:10.1371/journal.pone.0057148 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10658064 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Bumetanide Enhances Phenobarbital Efficacy in a Rat Model of Hypoxic Neonatal Seizures Ryan T. Cleary1, Hongyu Sun1, Thanhthao Huynh1, Simon M. Manning1,3, Yijun Li2, Alexander Rotenberg1, Delia M. Talos1, Kristopher T. Kahle5, Michele Jackson1, Sanjay N. Rakhade1, Gerard Berry2, Frances E. Jensen1,4* 1 Department of Neurology, Children’s Hospital Boston, Boston, Massachusetts, United States of America, 2 Division of Genetics and Metabolism, Children’s Hospital Boston, Boston, Massachusetts, United States of America, 3 Division of Newborn Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 4 Program in Neurobiology, Harvard Medical School, Boston, Massachusetts, United States of America, 5 Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America Abstract Neonatal seizures can be refractory to conventional anticonvulsants, and this may in part be due to a developmental increase in expression of the neuronal Na+-K+-2 Cl2 cotransporter, NKCC1, and consequent paradoxical excitatory actions of GABAA receptors in the perinatal period.
    [Show full text]
  • Dual Variable Domain Immunoglobulins and Uses Thereof
    (19) TZZ Z_T (11) EP 2 899 209 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.07.2015 Bulletin 2015/31 C07K 16/22 (2006.01) A61K 39/39 (2006.01) G01N 33/68 (2006.01) (21) Application number: 15153941.8 (22) Date of filing: 28.04.2009 (84) Designated Contracting States: • PHILLIPS, Andrew AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Libertyville, IL 60048 (US) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • WANG, Jieyi PT RO SE SI SK TR Lake Bluff, IL 60044 (US) Designated Extension States: • BELL, Randy, L. BA RS Mountain Green UT 84050 (US) (30) Priority: 29.04.2008 US 125834 P • NORVELL, Suzanne, M. 08.07.2008 US 134283 P Long Grove, IL 60047 (US) 23.10.2008 US 197191 P • LI, Yingchun 12.11.2008 US 199009 P Buffalo Grove, IL 60089 (US) • LIU, Junjian (62) Document number(s) of the earlier application(s) in Shrewsbury, MA 01545 (US) accordance with Art. 76 EPC: • YING, Hua 09739578.4 / 2 282 769 Holden, MA 01520 (US) (71) Applicant: Abbvie Inc. (74) Representative: Finnegan Europe LLP North Chicago, IL 60064 (US) 16 Old Bailey London EC4M 7EG (GB) (72) Inventors: • GHAYUR, Tariq Remarks: Holliston, MA 01746 (US) •Thecomplete document including Reference Tables • MORGAN-LAPPE, Susan, E. and the Sequence Listing can be downloaded from Chicago, IL 60656 (US) the EPO website • REILLY, Edward, B. •This application was filed on 05-02-2015 as a Libertyville, IL 60048 (US) divisional application to the application mentioned • KINGSBURY, Gillian, A.
    [Show full text]
  • Discovery of New AMPA Antagonist, Perampanel, Implication of Role in Seizure Disorders
    Discovery of New AMPA Antagonist, Perampanel, Implication of Role in Seizure Disorders 著者 花田 敬久 year 2015 その他のタイトル 新規AMPA型グルタミン酸受容体拮抗剤ぺランパネル の発見とけいれん性疾患における役割 学位授与大学 筑波大学 (University of Tsukuba) 学位授与年度 2015 報告番号 12102甲第7534号 URL http://hdl.handle.net/2241/00135054 Discovery of New AMPA Antagonist, Perampanel, Implication of Role in Seizure Disorders May 2015 Takahisa HANADA 1 Discovery of New AMPA Antagonist, Perampanel, Implication of Role in Seizure Disorders Dissertation Submitted to the Graduate School of Life and Environmental Sciences, the University of Tsukuba in Partial Fulfilment of the Requirements for the Degree of Doctor of Philosophy (Doctoral Program in Life Sciences and Bioengineering) Takahisa HANADA 2 Contents Chapter I. Preface Chapter II. Creation of new AMPA antagonist · Abstract · Introduction · Materials and Methods · Discussion and Conclusion · Figures and Tables Chapter III. Characterization as Therapeutic Agent for Epilepsy · Abstract · Introduction · Materials and Methods · Results · Discussion and Conclusion · Figures and Tables Chapter I V. Therapeutic treatment in Status Epilepticus · Abstract · Introduction · Materials and Methods · Results · Discussion and Conclusion · Figures and Tables Chapter V. Conclusion Chapter VI. Acknowledgements Chapter VII. References 3 Chapter I: Preface The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. Glutamate is a principal excitatory neurotransmitter in central nervous system (CNS). It causes strong excitation via activation of receptors at post synaptic membrane and elicits action potential when accumulation of receptor activity is occurred. It is also well recognized that glutamate receptor has a significant role in synaptic plasticity. It is therefore very important neurotransmitter in signal processing in CNS. Perturbation of glutamatergic neurotransmission could elicit various symptoms or diseases including seizures, abnormal movements, sensory abnormality, neuronal degeneration etc (Meldrum, 2000).
    [Show full text]
  • Neurochemical and Behavioral Features in Genetic Absence Epilepsy and in Acutely Induced Absence Seizures
    Hindawi Publishing Corporation ISRN Neurology Volume 2013, Article ID 875834, 48 pages http://dx.doi.org/10.1155/2013/875834 Review Article Neurochemical and Behavioral Features in Genetic Absence Epilepsy and in Acutely Induced Absence Seizures A. S. Bazyan1 and G. van Luijtelaar2 1 Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Science, Russian Federation, 5A Butlerov Street, Moscow 117485, Russia 2 Biological Psychology, Donders Centre for Cognition, Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen, P.O. Box 9104, 6500 HE Nijmegen, The Netherlands Correspondence should be addressed to G. van Luijtelaar; [email protected] Received 21 January 2013; Accepted 6 February 2013 Academic Editors: R. L. Macdonald, Y. Wang, and E. M. Wassermann Copyright © 2013 A. S. Bazyan and G. van Luijtelaar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The absence epilepsy typical electroencephalographic pattern of sharp spikes and slow waves (SWDs) is considered to be dueto an interaction of an initiation site in the cortex and a resonant circuit in the thalamus. The hyperpolarization-activated cyclic nucleotide-gated cationic Ih pacemaker channels (HCN) play an important role in the enhanced cortical excitability. The role of thalamic HCN in SWD occurrence is less clear. Absence epilepsy in the WAG/Rij strain is accompanied by deficiency of the activity of dopaminergic system, which weakens the formation of an emotional positive state, causes depression-like symptoms, and counteracts learning and memory processes.
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]